“The current condition has uncovered some structural weaknesses within the EU’s medicines provide chain and also a superior dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She advisable that provide chain problems be tackled in an EU pharmaceutical tactic